These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 32320027)

  • 21. Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate or Severe Acne Vulgaris in Adult Females.
    Harper JC; Baldwin H; Stein Gold L; Guenin E
    J Drugs Dermatol; 2019 Nov; 18(11):1147-1154. PubMed ID: 31741360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-Severe Acne Vulgaris in an Adult and Adolescent Female Population.
    Kircik LH; Baldwin H; Lain E; Guenin E; Harris S; Bhatt V
    J Drugs Dermatol; 2019 Feb; 18(2):178-188. PubMed ID: 30811141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis.
    Tanghetti EA; Werschler WP; Lain E; Guenin E; Harris S; Loncaric A; Pillai R
    J Drugs Dermatol; 2020 Mar; 19(3):272-279. PubMed ID: 32549090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topical Clascoterone: The First Novel Agent for Acne Vulgaris in 40 Years.
    Piszczatoski CR; Powell J
    Clin Ther; 2021 Oct; 43(10):1638-1644. PubMed ID: 34607697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acne treatment efficacy of intense pulsed light photodynamic therapy with topical licochalcone A, l-carnitine, and decanediol: A spilt-face, double-blind, randomized controlled trial.
    Wanitphakdeedecha R; Tavechodperathum N; Tantrapornpong P; Suphatsathienkul P; Techapichetvanich T; Eimpunth S; Manuskiatti W
    J Cosmet Dermatol; 2020 Jan; 19(1):78-87. PubMed ID: 31587493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3 %/Benzoyl Peroxide 2.5 % Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study.
    Stein Gold L; Weiss J; Rueda MJ; Liu H; Tanghetti E
    Am J Clin Dermatol; 2016 Jun; 17(3):293-303. PubMed ID: 26945741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males.
    Cook-Bolden FE; Gold MH; Guenin E
    J Drugs Dermatol; 2020 Jan; 19(1):78-85. PubMed ID: 32023013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical epidermal growth factor for the improvement of acne lesions: a randomized, double-blinded, placebo-controlled, split-face trial.
    Kim HK; Yeo IK; Li K; Kim BJ; Kim MN; Hong CK
    Int J Dermatol; 2014 Aug; 53(8):1031-6. PubMed ID: 24962549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials.
    Tanghetti EA; Werschler WP; Lain T; Guenin E; Martin G; Pillai R
    J Drugs Dermatol; 2020 Jan; 19(1):70-77. PubMed ID: 31985914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Assessment of Efficacy and Safety in Patients Aged 9 Years and Older.
    Tyring SK; Kircik LH; Pariser DM; Guenin E; Bhatt V; Pillai R
    J Drugs Dermatol; 2018 Oct; 17(10):1084-1091. PubMed ID: 30365589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Impact of Gender and Race on Efficacy and Safety.
    Lain E; Day D; Harper J; Guenin E
    J Drugs Dermatol; 2019 Nov; 18(11):1128-1138. PubMed ID: 31741356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials.
    Eichenfield LF; Lain T; Frankel EH; Jones TM; Chang-Lin JE; Berk DR; Ruan S; Kaoukhov A
    J Drugs Dermatol; 2016 Aug; 15(8):962-9. PubMed ID: 27537997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials.
    Stein Gold LF; Jarratt MT; Bucko AD; Grekin SK; Berlin JM; Bukhalo M; Weiss JS; Berk DR; Chang-Lin JE; Lin V; Kaoukhov A
    J Drugs Dermatol; 2016 May; 15(5):553-61. PubMed ID: 27168264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of a Phase 2, Randomized,Vehicle-Controlled Study Evaluating the Efficacy,Tolerability, and Safety of Daily or Twice Daily SB204 for the Treatment of Acne Vulgaris.
    Eichenfield LF; Gold LS; Nahm WK; Cook-Bolden FE; Pariser DM
    J Drugs Dermatol; 2016 Dec; 15(12):1496-15027. PubMed ID: 28095573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.
    Shalita AR; Berson DS; Thiboutot DM; Leyden JJ; Parizadeh D; Sefton J; Walker PS; Gibson JR;
    Clin Ther; 2004 Nov; 26(11):1865-73. PubMed ID: 15639698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topical Clascoterone for Acne Vulgaris.
    Burma NE; Woo TE; Parsons L
    Skin Therapy Lett; 2022 Jan; 27(1):1-3. PubMed ID: 35081302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Photodynamic therapy with methyl aminolaevulinate 80 mg g(-1) for severe facial acne vulgaris: a randomized vehicle-controlled study.
    Pariser DM; Eichenfield LF; Bukhalo M; Waterman G; Jarratt M;
    Br J Dermatol; 2016 Apr; 174(4):770-7. PubMed ID: 26663215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual Comparison.
    Dréno B; Bissonnette R; Gagné-Henley A; Barankin B; Lynde C; Kerrouche N; Tan J
    Am J Clin Dermatol; 2018 Apr; 19(2):275-286. PubMed ID: 29549588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clascoterone: a new topical anti-androgen for acne management.
    Santhosh P; George M
    Int J Dermatol; 2021 Dec; 60(12):1561-1565. PubMed ID: 34242398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.
    Eichenfield LF; Simpson EL; Papp K; Szepietowski JC; Blauvelt A; Kircik L; Silverberg JI; Siegfried EC; Kuligowski ME; Venturanza ME; Kallender H; Ren H; Paller AS
    Am J Clin Dermatol; 2024 Jul; 25(4):669-683. PubMed ID: 38698175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.